The Agency for Healthcare and Research Quality (AHRQ) is requesting supplemental evidence and data for research protocols for Integrated Pain Management Programs. Submission deadline is December 8, 2020. Read more.
The Agency for Healthcare and Research Quality (AHRQ) is requesting supplemental evidence and data for research protocols for Integrated Pain Management Programs. Submission deadline is December 8, 2020. Read more.
The National Prescription Drug Take Back Day aims to provide a safe, convenient, and responsible means of disposing of prescription drugs, while also educating the general public about the potential for abuse of medications. Read more.
AAPM joined other pain groups in protesting the proposed expansion of a CMS rule that would increase prior authorization requirements for implanted spinal neurostimulators to curb potential unnecessary utilization. Read more.
AAPM joined other pain groups in protesting the proposed expansion of a CMS rule that would increase prior authorization requirements for implanted spinal neurostimulators to curb potential unnecessary utilization. Full letter.
A new cross-sectional study uncovers shortcomings in pivotal trials supporting new drug applications for opioid analgesics, which range from study design to duration. Read more.
About 1 in 12 adults in the United States have high-impact chronic pain. Healthy People 2030 focuses on helping people with high-impact chronic pain safely manage their pain and reduce its impact. View chronic pain objectives.
The free two-day virtual workshop, jointly organized by the National Center for Complementary and Integrative Health and the National Institute of Biomedical Imaging and Bioengineering at NIH, will take place online September 16–17. See Draft Agenda and Register.
The new report details the recent evolution of the nation’s opioid epidemic and physicians’ progress toward ending it. AAPM Past President Steve Stanos, DO, represents the Academy on the Task Force. Key points from the 2020 report include: opioid prescribing decreases for a sixth year in a row, Prescription Drug Monitoring Program (PDMP) registrations and use continue to increase, more physicians are certified to treat opioid use disorder, and access to naloxone is increasing. Read full report.
The Centers for Disease Control and Prevention (CDC) recently announced an opportunity for stakeholders to share their individual perspectives on and experiences with pain and pain management, including but not limited to the benefits and harms of opioid use. Patients with acute or chronic pain, patients’ family members and/or caregivers, and healthcare providers who care for patients with pain or conditions that can complicate pain management (e.g., opioid use disorder or overdose) will be considered for participation.
CDC will hold approximately 100 individuals, 45- to 60-minute conversations with selected stakeholders over the phone or through an internet-enabled virtual platform. Input gathered through these conversations will help inform CDC’s understanding of stakeholders’ values and preferences relate to pain and pain management and will complement its ongoing work to update the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain.
The conversations are intended to supplement the written comments on the same subject, gathered through a June docket. AAPM responded to this initial call, submitting feedback on the following topic areas:
Persons interested in participating in the current call for comments should contact CDC no later than 5:00 p.m. EDT August 21, 2020.
FDA is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder (OUD) to add new recommendations about naloxone to the prescribing information. This will help ensure that health care professionals discuss the availability of naloxone and assess each patient’s need for a naloxone prescription when opioid pain relievers or medicines to treat OUD are being prescribed or renewed. The patient Medication Guides will also be updated. Full story.